Kalaris Therapeutics (KLRS) Shares Outstanding (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Shares Outstanding (Entity) of $23.0 million for Q1 2026, up 467.27% year-over-year from $4.1 million in Q1 2025, and up 50.59% quarter-over-quarter from $15.3 million in Q4 2025.
Kalaris Therapeutics (KLRS) Shares Outstanding (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $23.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 467.27% year-over-year to $23.0 million; the TTM figure through Mar 2026 stood at $23.0 million (up 467.27% YoY), while the FY2025 annual figure was $15.3 million, up 204.84% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $23.0 million, up from $15.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $23.0 million in Q1 2026, with the low at $2.8 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $5.0 million (2023), against an average of $7.7 million.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) declined 18.86% in 2025, then jumped 467.27% in 2026.
- Kalaris Therapeutics' Shares Outstanding (Entity) stood at $3.3 million in 2022, then jumped by 48.91% to $5.0 million in 2023, then advanced by 0.91% to $5.0 million in 2024, then soared by 204.84% to $15.3 million in 2025, then soared by 50.59% to $23.0 million in 2026.
- Business Quant data shows KLRS's Shares Outstanding (Entity) at $23.0 million in Q1 2026, $15.3 million in Q4 2025, and $18.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | 23.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.80 Mn |
| Mar 31, 2026 | 23.72 Mn |
| Dec 31, 2025 | 15.27 Mn |
| Sep 30, 2025 | 18.70 Mn |
| Jun 30, 2025 | 18.70 Mn |
| Mar 31, 2025 | 4.05 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | 5.02 Mn |
| Jun 30, 2024 | 5.01 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Dec 31, 2023 | 4.52 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 4.11 Mn |
| Mar 31, 2023 | 4.06 Mn |
| Dec 31, 2022 | 3.33 Mn |
| Sep 30, 2022 | 3.69 Mn |
| Jun 30, 2022 | 2.80 Mn |
| Mar 31, 2022 | 2.78 Mn |
| Dec 31, 2021 | 2.73 Mn |
| Sep 30, 2021 | 2.74 Mn |